Latest Share Chat

REMOVE ADS

Ip Group Share News (IPO)

Ip Group Information

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes

Get Live Data

64.00 0.30 (0.47%)

Bid:

63.60

Ask:

64.30

Spread: 0.70 (1.101%)

Market Cap: £565.39m

Last checked at -

Intraday Ip Group Share Chart

REMOVE ADS

Ip Group News

IP Group puts another £3.8m into cybersecurity firm Garrison

(Sharecast News) - Intellectual property-based business developer IP Group said on Monday that its portfolio company Garrison Technology, a specialist...

IP Group Investee Garrison Technology Closes GBP23 Million Fundraising

LONDON (Alliance News) - IP Group PLC on Monday said its portfolio company Garrison Technology Ltd completed a GBP22.9 million fundraising.The develop...

LONDON MARKET CLOSE: Stocks End Lower On Chinese And Italian Woes

LONDON (Alliance News) - Stocks closed lower Monday on the actions of the Chinese and Italian governments, as the pound continued its fall on news fro...

Diurnal Group Child Adrenal Insufficiency Drug Approved In Scotland

LONDON (Alliance News) - Diurnal Group PLC said Monday the Scottish Medicines Consortium approved the routine use of Alkindi, a first-line treatment o...

LONDON MARKET MIDDAY: China Prompts Sell-Off In Europe; Insurers Fall

LONDON (Alliance News) - Share prices in London had slipped firmly into the red by midday on Monday following a slump in Chinese equities overnight."E...

WINNERS & LOSERS SUMMARY: French Connection In Vogue On Possible Sale

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - up 1.0%...

Diurnal's endocrine drug does not meet trial objective

(Sharecast News) - Clinical trials of Diurnal Group's Chronocort drug failed to meet the primary objective of proving superior to conventional therapy...

Shares In IP Group, Diurnal Suffer After Chronocort Trial Disappoints

LONDON (Alliance News) - Diurnal Group PLC said Monday its phase-three European trial of Chronocort did not meet its primary objective, causing shares...